Privacy Policy

Projects In Knowledge is committed to protecting the privacy and confidentiality of visitors to our Web site. While Projects In Knowledge does not require that you provide us with personally identifiable information in order to visit our Web site, please note that in order to participate in the continuing medical education activities that we provide, it will be necessary for you to register with us and provide this information.

About this Privacy Policywww.projectsinknowledge.com is our Web site for physicians and allied health care professionals, although it is open to non-professionals as well. The purpose of projectsinknowledge.com is to provide continuing medical education for healthcare professionals, and is intended for use only by a licensed healthcare professional.

Projects In Knowledge is the name we use to refer to our entire company, even though our formal corporate name is Projects In Knowledge, Inc. When we refer to ourselves as "we" or "Projects In Knowledge," we mean our company, Projects In Knowledge, Inc., including any subsidiary that we control (for example, a subsidiary that we own). We may share information among our subsidiaries that we own or control, but it is always protected under the terms of this privacy policy.

This privacy policy applies only to the Projects In Knowledge Web site. You should read the privacy policy at each Web site that you visit after you leave our site. We are not responsible for how other Web sites treat your privacy, once you leave the Projects In Knowledge site.

Privacy Policy Changes
If we change our privacy policy, we will post those changes on this page. Users should check this policy to keep abreast of any changes.

Information We Collect
In this section of our privacy policy, we discuss the different types of information we may collect about you, and the ways in which we collect them.

Information We Collect from Unregistered Visitors
Visitors to our Web site can access the Web site's home page and browse the site without disclosing any personally identifiable information. We do track information provided to us by your browser, including the Web site you came from (known as the "referring URL"), the type of browser you use, the time and date of access, and other information that does not personally identify you.

Information We Collect When You Register
Customers registering on our Web site for continuing medical education activities we provide are asked to provide us with identifying information, such as name, contact information, and other identifying information. On our registration screens, we clearly label which information is required for registration, and which information is optional and may be given at your discretion.

On our registration screens you will also find a Burning Question field. Submission of a Burning Question is completely voluntary. By submitting a Burning Question, you grant Projects In Knowledge the right to share it with faculty to consider as they prepare their continuing medical education presentations.

Listserves
When you are using a listserve—or member-only discussion board— on our Web site, you are posting a message and your user name, which is available for all registered members to see. You should not post any information to our listserves you want to keep private. It is a condition of our Web site that when participating in a listserve, you do not:

Restrict or inhibit any other user from using the listserve

Post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including, without limitation, any transmission constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or foreign law

Post or transmit any information, software or other material which violates or infringes upon the rights of others, including material which constitutes an invasion of privacy or infringement of publicity rights or which is protected by copyright, trademark or other proprietary right, or derivative works thereof, without first obtaining permission from the owner or right holder

Post or transmit any information, software or other material which contains a virus or other harmful component

Post, or transmit, or in any way exploit any information, software or other material for commercial purposes which contains advertising, promotions or marketing

By sending a message through the listserve, you grant Projects In Knowledge the non-exclusive right and license to display, copy, publish, distribute, transmit, print, and use such information. Projects In Knowledge reserves the right to terminate your access to, and use of, the listserve if you do not abide by these conditions.

Use of Cookies
Cookies are a technology used by the Projects In Knowledge Web site to identify a user as the user moves through the Web site. Your browser allows us to place some information on your computer's hard drive that identifies the computer you are using. We use cookies to track your usage throughout our Web site.

Your Web browser can be set to allow you to control whether you will accept cookies, reject cookies, or to notify you each time a cookie is sent to you. If your browser is set to reject cookies, Web sites that are cookie-enabled will not recognize you when you return to the Web site, and some Web site functionality may be lost. The Help section of your browser will tell you how to prevent your browser from accepting cookies.

Although cookies do not normally contain personally identifiable information, if you are a registered user we may associate your registration information with cookies our Web site places on your computer's hard drive. Associating a cookie with your registration data allows us to offer increased personalization and functionality. For example, you can elect to have our Web site "remember" you and bypass the registration process each time you register for one of our educational activities. Without cookies, this functionality would not be possible. Projects In Knowledge does not currently employ cookies for this use, but is considering it to make our registration processes more efficient for you.

Children's Privacy
Projects In Knowledge's Web site is designed and intended for use by adults, and is not intended for, nor designed to be used by children under the age of 18, or any other unlicensed, untrained individuals. We do not collect personally identifiable information from any person we know is a child under the age of 18.

Uses We Make of Information
In this section of our privacy policy, we identify the ways we may use information about you that we have collected.

Aggregate Data
We create aggregate data about visitors to our Web site for activity development and improvement. We also use it for market analysis. We may provide information from our Web site in aggregate form, with identifying information removed, to third parties. For example, we may tell a third party what percentage of our registered users reside in a particular geographical area. When aggregated information is provided, we pool it from many individual records and strip it of any data that could be used to identify an individual before it is used. Any third party that receives aggregated data must agree not to attempt to re-identify the people it belongs to. Projects In Knowledge does not sell any user data to any third party for commercial purposes.

Third Parties
In addition to aggregate information (discussed previously), we may share some kinds of information with third parties as described below.

Business Transfers: If we transfer a business unit (such as a subsidiary) or an asset (such as a Web site) to another company, we will require them to honor the applicable terms of this privacy policy.

Protection of Information
In this section of our privacy policy, we discuss the security measures we take to protect information that we have collected about you.

General Policies
We have implemented technology and security policies, rules and other measures to protect the personal data that we have under our control from unauthorized access, improper use, alteration, unlawful or accidental destruction, and accidental loss. We also protect your information by requiring that all our employees and others who have access to or are associated with the processing of your data respect your confidentiality. In addition, we have appropriate security measures in place in our physical facilities to protect against the loss or misuse of information at our site that we have collected from you.

Projects In Knowledge Employees
Projects In Knowledge employees are required to keep customer information private, as a condition of their employment with the company. Only selected, authorized Projects In Knowledge employees are permitted to access your registration information.
Employees are required to sign a confidentiality agreement. All employees and contractors must abide by our privacy policy, and those who violate that policy are subject to disciplinary action, up to and including termination of their employment and legal action.

Privacy Questions or Concerns about Our Web Site
For privacy questions or concerns about the Projects In Knowledge Web site, please contact privacy@projectsinknowledge.com.

This CME/CE activity has reached its termination date and no longer offers continuing education credit. Please note that expired CME/CE activities may not contain the most up-to-date information available.

In this case presentation, Corey J. Langer, MD, FACP, illustrates the role of the EML4-ALK fusion oncogene in personalized medicine for non-small cell lung cancer. EML4-ALK testing and current efficacy and safety data of critozinib "a first-in-class ALK inhibitor entering phase III testing" inform treatment selection and management for a never-smoker woman diagnosed at the age of 67 years.

Pharmacists

Estimated time for completion of this activity:

Target Audience

This activity is designed for oncologists, as well as nurse practitioners, nurses, and pharmacists, who specialize in and care for patients with lung cancer.

Activity Goal

The goal of this CME/CE activity is to examine current and emerging strategies for treating and managing patients with lung cancer.

Learning Objective (s)

Assess the incidence and implications of the EML4-ALK fusion oncogene in patients with nonâsmall-cell lung cancer to determine who may benefit from treatment with an ALK inhibitor.

Evaluate treatment options for patients with nonâsmall-cell lung cancer who are positive for the EML4-ALK fusion oncogene to improve patient outcomes.

CME Information: Physicians

Statement of Accreditation

Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Projects In Knowledge® designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CE Information: Nurses

Projects In Knowledge® (PIK) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Projects In Knowledge is also an approved provider by the California Board of Registered Nursing, Provider Number CEP-15227.

Upon completion of this course, participants will be awarded 0.86 nursing contact hour(s).

DISCLAIMER: Accreditation refers to educational content only and does not imply ANCC, CBRN, or PIK endorsement of any commercial product or service.

CE Information: Pharmacists

Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This Tx Reporter Newsletter is worth up to 1.5 contact hour(s) (0.15 CEU). The ACPE Universal Activity Number assigned to this Application-type activity is 0052-0000-10-2672-H01-P.

Pharmacists should only claim credit commensurate with the extent of their participation in the activity.

CME/CE Instructions

To obtain CME/CE credit:

Read or listen to each activity carefully.

Complete/submit each posttest and evaluation.

Instantly access and print out your certificate.

There is no fee for this activity.

CONTRACT FOR MUTUAL RESPONSIBILITY IN CME/CE

Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.

The Disclosure Policy of Projects In Knowledge® requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.

Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.

The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.

Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.

Please click the "Agree" button to attest that you have read and understood the CME/CE required elements.

Pharmacists

Estimated time for completion of this activity:

Target Audience

This activity is designed for oncologists, as well as nurse practitioners, nurses, and pharmacists, who specialize in and care for patients with lung cancer.

Activity Goal

The goal of this CME/CE activity is to examine current and emerging strategies for treating and managing patients with lung cancer.

Learning Objective (s)

Assess the incidence and implications of the EML4-ALK fusion oncogene in patients with nonâsmall-cell lung cancer to determine who may benefit from treatment with an ALK inhibitor.

Evaluate treatment options for patients with nonâsmall-cell lung cancer who are positive for the EML4-ALK fusion oncogene to improve patient outcomes.

CME Information: Physicians

Statement of Accreditation

Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Projects In Knowledge® designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CE Information: Nurses

Projects In Knowledge® (PIK) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Projects In Knowledge is also an approved provider by the California Board of Registered Nursing, Provider Number CEP-15227.

Upon completion of this course, participants will be awarded 0.86 nursing contact hour(s).

DISCLAIMER: Accreditation refers to educational content only and does not imply ANCC, CBRN, or PIK endorsement of any commercial product or service.

CE Information: Pharmacists

Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This Tx Reporter Newsletter is worth up to 1.5 contact hour(s) (0.15 CEU). The ACPE Universal Activity Number assigned to this Application-type activity is 0052-0000-10-2672-H01-P.

Pharmacists should only claim credit commensurate with the extent of their participation in the activity.

CME/CE Instructions

To obtain CME/CE credit:

Read or listen to each activity carefully.

Complete/submit each posttest and evaluation.

Instantly access and print out your certificate.

There is no fee for this activity.

CONTRACT FOR MUTUAL RESPONSIBILITY IN CME/CE

Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.

The Disclosure Policy of Projects In Knowledge® requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.

Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.

The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.

Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.

Want to listen to what the experts have to say? Just click on the hyperlinks that appear right before the microphone icons throughout the text on this webpage to access faculty audio commentary.

Patient Description

Ms K, a 67-year-old white female and never-smoker, presented with dyspnea on exertion and vague right upper quadrant pain. Physical examination disclosed a 2-cm right supraclavicular node (SCN) and diminished breath sounds in the right lung. Chest X-ray demonstrated a 3-cm mass in the right upper lobe and a right pleural effusion. Computed tomography (CT) confirmed the presence of a 3.2-cm right upper lobe mass with multiple ipsilateral and contralateral pulmonary nodules and a moderate-size right pleural effusion, and at least ten space-occupying lesions in the liver ranging in size from 10 to 20 mm. Mediastinal windows confirmed right hilar and paratracheal nodes and right SCN. Magnetic resonance imaging (MRI) of the brain proved negative.

The patient underwent right SCN biopsy, which revealed adenocarcinoma positive for thyroid transcription factor-1 (TTF-1). Tissue was sent for KRAS and epidermal growth factor receptor (EGFR) gene mutation testing, and both returned negative or "wild type."

A decision was made to start combination bevacizumab with paclitaxel and carboplatin. The patient had a profound partial response with resolution of the pleural effusion, right SCN, and pulmonary nodules and 50% shrinkage of the primary lesion, hilar and mediastinal nodes, and liver metastases. After six cycles, she went onto maintenance therapy with bevacizumab alone. Unfortunately, after four cycles of maintenance bevacizumab, dyspnea on exertion and cough recurred. Follow-up CT demonstrated growth of the primary tumor and reappearance of pulmonary nodules. In addition, the liver metastases had doubled in size.

Clinical Decision Point 1a: EML4-ALK Mutation Testing

Question 1a: Should this patient be evaluated for the EML4-ALK fusion oncogene?

Yes

No

Discussion
(a) Approximately 5% of patients diagnosed with advanced non-small-cell lung cancer (NSCLC), or more than 70,000 individuals annually worldwide, harbor the fusion oncogene made up of portions of the echinoderm microtubule-associated protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene.1 The significance of the EML4-ALK fusion oncogene is that emerging ALK inhibitors have shown clinical efficacy in patients with NSCLC who have this oncogene.1 The relative likelihood of EML4-ALK is far higher in never-smokers or former light smokers (â¤10 pack years and quit â¥1 year ago) and in those with adenocarcinoma of the lung.1 It is also higher in individuals with wild type EGFR and KRAS, because according to current data, EGFR or KRAS mutations and EML4-ALK appear to be mutually exclusive.2,3 The chance, therefore, of having EML4-ALK is even higher in patients with the candidate phenotype who are wild type for EGFR and KRAS. Given the patient's phenotype and EGFR status, it is appropriate to test her for the EML4-ALK.

Soda et al first reported the EML4-ALK fusion oncogene in 2007 after discovering it in a lung adenocarcinoma specimen surgically resected from a 62-year-old man with a history of smoking.4EML4-ALK results from an alteration on the short arm of chromosome 2 at the point of 2p21-p23 (Figure 1).5,6 Although first described by Soda as an inversion,4 more complex cytogenetic alterations, including amplification, have since been identified.5 While multiple breakpoints in different EML4 exons may occur, all variants preserve the intracellular tyrosine kinase domain of ALK and the coiled-coil domain of EML4.1 Other ALK fusion partners exist in NSCLC, including TFG and KIF5B.1 Mutations involving ALK are oncogenic due to the transforming activity, usually by dimerization, of the fusion partner on ALK's tyrosine kinase activity, leading to increased cell proliferation.1,7

ALK inhibitors target the aberrant ALK tyrosine kinase and its proliferative activity in much the same way that erlotinib and gefitinib target the tyrosine kinase activity of EGFR in NSCLC patients with EGFR mutations. A recent two-part phase I trial studied the ALK inhibitor PF02341066, or crizotinib.8,9 Crizotinib is an oral drug belonging to the new class of c-met/hepatocyte growth factor receptor (HGFR) tyrosine kinase inhibitors10 with dual inhibition of ALK and MET tyrosine kinases.11 Part one of the phase I trial was a dose-escalation study that evaluated crizotinib, 50 mg once daily to 300 mg twice daily, in patients with a variety of advanced and refractory solid tumors, including NSCLC.8,9 The maximum tolerated dose was established at 250 mg twice daily due to dose-limiting fatigue in the cohort receiving 300 mg twice daily.9 Part two of the phase I trial continued the evaluation of crizotinib (250 mg BID only) in an expansion cohort, enrolling 82 patients with advanced, largely "refractory" NSCLC who were positive for the EML4-ALK fusion oncogene.9 Data available as of April 7, 2010 were published in the October 28 issue of The New England Journal of Medicine. These data showed that 47 of 82 patients (57%) achieved a response, including 46 partial responses and 1 complete response, after a mean treatment duration of 6.4 months with follow-up ongoing. Although progression-free survival was not an end point of this study and median progression-free survival was not reached at 6 months as of the data cut-off date, the probability of 6-month progression-free survival was estimated at 72%. The most common adverse events were grade 1 gastrointestinal events and visual disturbances. Mild to moderate increases in liver transaminases were also observed.

Updated results from the expansion cohortâwith a total of 113 patients in the database and data available as of August 7, 2010âwere reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy in October 2010.12 An objective response (complete or partial) was achieved by 56.2% of patients with a median duration of response of 36.3 weeks. Figure 2 shows the tumor response by patient. The median progression-free survival was 9.2 months, with a median duration of follow-up of 8.0 months. A total of 54 patients continue to be followed for progression-free survival.

Discussion
(a) It would be most convenient for the patient to have the original biopsy evaluated for the EML4-ALK translocation. This approach also avoids the morbidity of a repeat biopsy. If the tissue were depleted or unavailable, then a core biopsy would be necessary. Liver biopsy would be more likely to provide adequate material. Is it important to note that testing for EML4-ALK in potential clinical trial candidates mandates tissue, ie, formalin-fixed, paraffin-embedded (FFPE) tumor samples, not merely cytology.9

Currently, there is no standard method for detecting EML4-ALK in lung tissue, although a number of diagnostic techniques are available.1 Reverse-transcriptase (RT)-PCR is an extremely sensitive method, but has some procedural technical challenges, including the potential for false positives.1 Importantly, RT-PCR is more difficult to perform on FFPE tissues, compared with fresh tissues, due to the high degradation of extracted RNA.1

Fluorescence in situ hybridization (FISH) can also be used to identify EML4-ALK.1 A split signal using the appropriate probe suggests the presence of any inter-chromosomal or intra-chromosomal ALK mutation, including those not involving EML4.1 False negatives are possible with this method, however, due to the subtle split signal often associated with EML4-ALK mutations.1 Additionally, tissue morphology may be disrupted when FFPE tissue is used.1 FISH was the detection method used in phase I crizotinib testing.9 Samples were considered positive for an ALK rearrangement if more than 15% of scored tumor cells had split signals.9 Whether EML4 was the specific fusion partner was confirmed by RT-PCR.9

Immunohistochemistry (IHC) analysis has the advantage of maintaining tissue morphology and is a methodology common to pathology laboratories.1 Its application to the detection of ALK mutations in NSCLC is not clinically practical, however, due to the low level of ALK expression and the potential for weak staining.1

Case Continues
Work-up of the patient's original SCN specimen proved positive for EML4-ALK. Enrollment in a clinical trial was discussed with the patient. Two separate trials of crizotinib are currently recruiting patients with EML4-ALK. The phase III trial (PROFILE 1007) is an open-label trial enrolling patients who have had exposure to one prior platinum-containing chemotherapy regimen, randomizing them to either crizotinib or standard chemotherapy (docetaxel or pemetrexed).13 A separate phase II open-label trial (PROFILE 1005) is evaluating single-agent crizotinib in patients who have received two or more prior systemic regimens.14

The patient was enrolled in PROFILE 1007 and was randomized to oral crizotinib 250 mg BID on a continuous schedule. After 6 months, she achieved 90% tumor regression.

Discussion(c) In the absence of disease progression or toxicity, there is no empiric reason to stop therapy. To date, there have been no reports of cumulative toxicity or late, dangerous complications, associated with crizotinib. In phase I testing, therapy with crizotinib continued until patients progressed or developed intolerable adverse events.9 As of April 7, 2010, 19 patients had discontinued treatment for the following reasons: disease progression, 13; crizotinib-related adverse event, 1 (recurrence of grade 3 ALT despite dose reduction); nondrug-related adverse events, 1; death from unrelated causes, 2; and, other, 2.9 Among the initial 82 patients with NSCLC, 63 patients (77%) continued to receive crizotinib after the study's data cutoff.9 Twelve patients received therapy for at least 40 weeks, 8 for at least 50 weeks, 3 for at least 70 weeks, and 1 for more than 80 weeks.9 As of August 7, 2010, a total of 36 patients out of 113 had discontinued treatment: disease progression, 23; drug-related adverse events, 1; non-drug-related adverse events, 2; death, 7; withdrawal of consent, 1; and other, 2.12

One case report has been published about ALK resistance mutations with crizotinib use.15 The patient was in the expansion cohort of the phase I trial. After 5 months of treatment, during which time the subject achieved a partial response, disease progression developed. Molecular analysis detected two distinct acquired mutations, which conferred resistance to multiple ALK inhibitors.

Although resistance may develop over time with any targeted therapy, any future potential risk of resistance is not a reason to truncate therapy that is producing good response in a patient. The development of resistance will be manifest in disease progression. If and when that occurs, the patient should be evaluated for ALK resistance mutations. If present, the patient may then be considered for a study targeting patients who have developed clinical resistance.

Case ContinuesThe patient remained free of progression for more than 1 year before her cancer again progressed. Although her chest disease remained responsive, her liver metastases began to grow. She underwent re-biopsy and proved to have an ALK resistance mutation.

Clinical Decision Point 3: Third-Line Therapy

Question 3: Which of the following options should be ruled out at this point?

Discussion(c) For this patient, erlotinib and gefitinib should be ruled out as the next step, although this approach could be entertained later if all other strategies failed. As is typical of patients with EML4-ALK translocation, this patient does not have an EGFR mutation, and therefore, would likely be insensitive to an EGFR tyrosine kinase inhibitor such as erlotinib or gefitinib.3 Better options include initiating pemetrexed or enrolling the patient in a clinical trial.

Pemetrexed would be the standard approach in this situation. It is FDA approved for the treatment of patients with locally advanced or metastatic nonsquamous NSCLC after prior chemotherapy.16 With therapeutic equivalence to docetaxel in this setting, pemetrexed is considerably less toxic.17 In addition, pemetrexed may have a preferential advantage in patients with adenocarcinoma compared with docetaxel.18

If the patient is reasonably asymptomatic and motivated, it would be appropriate to proceed with a phase I clinical trial geared toward overcoming ALK inhibitor resistance. A number of emerging kinase inhibitors are in development that may have the potential to overcome crizotinib-related ALK resistance mutations either by increased potency or by efficacy against the mutations.19 Phase I trials of AKT kinase inhibitor GSK-2141795 as monotherapy20 or in combination with mitogen-activated protein kinase inhibitor GSK1120212 are currently recruiting.21 (AKT is a downstream signaling target of activated ALK.22) ALK kinase inhibitors in preclinical development include CEP-28122 and AP-26113, with investigational new-drug applications expected soon, and X-276.19

Case Continues Because of logistical issues precluding out-of-town travel for a clinical trial evaluating therapies to overcome ALK inhibitor resistance, the patient opted for standard chemotherapy. (It is important to note that in general, patients positive for EML4-ALK are often sensitive to chemotherapy.3) She went on to receive pemetrexed 500 mg/m2 IV every 3 weeks with folic acid and vitamin B12 support and has had a 20% tumor regression to date after three cycles.

Conclusion

First reported in 2007, EML4-ALK has become an important new target for approximately 5% of patients with NSCLC. Those who harbor this fusion oncogene appear to be extraordinarily sensitive to crizotinib, a first-in-class ALK inhibitor. This breakthrough has opened up therapeutic options that did not previously exist, but crizotinib is not a panacea or cure. Responses are often profound, but progression is likely to be inevitable in the vast majority of patients. Strategies to overcome or mitigate resistance are essential, but still fledgling. Patients with the EML4-ALK fusion oncogene may still be sensitive to conventional cytotoxics. Clinical testing of crizotinib is ongoing to fully determine efficacy and safety, and other emerging kinase inhibitors, active against EML4-ALK, are also in development.

Compassionate Use

The FDA allows the use of investigational drugs in patients outside of clinical trials on a case-by-case basis as part of an "expanded access" (also called "compassionate use") program, contingent upon manufacturer participation.23 Patients or their healthcare providers can contact a drug's manufacturer to inquire whether a drug is available through expanded access, and if so, what the policies and procedures are for access.